Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667937 | 0.86 | CPB2 (0.44) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1667938 | 0.86 | CPB2 (0.44) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL201189 | 0.85 | CPB2 (0.42) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL201190 | 0.85 | CPB2 (0.42) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10612551 | 0.84 | CPB2 (0.38) | CPB2CPB1CYP1A2CYP3A4 | |
| SCHEMBL10777853 | 0.84 | CPB2 (0.40) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7074055 | 0.84 | CPB2 (0.40) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL147911 | 0.84 | CPB2 (0.38) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL28558505 | 0.84 | CPB2 (0.38) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6009497 | 0.83 | CPB2 (0.36) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | CPB2 2366/4885CPB1 2924/4885MAPT 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.